TY  - JOUR
AU  - García-García, José A
AU  - Pérez-Quintana, Marta
AU  - Ramos-Giráldez, Consuelo
AU  - Cebrián-González, Isabel
AU  - Martín-Ponce, María L
AU  - Del Valle-Villagrán, José
AU  - Navarro-Puerto, María A
AU  - Sánchez-Villegas, Jorge
AU  - Gómez-Herreros, Rocío
AU  - Manoja-Bustos, Isabel
AU  - León-Martí, Daniel
AU  - Serrano-Rodríguez, Lucía
AU  - de Miguel-Albarreal, Alejandra
AU  - Velasco-Romero, María J
AU  - Mula-Falcón, Francisco
AU  - Fernández-Pérez, Pilar
AU  - Melguizo-Moya, Isabel
AU  - Pérez-Quintana, María J
AU  - Romero-Molina, Guillermo
AU  - Vergara-López, Salvador
AU  - Marenco-de la Fuente, José L
AU  - Marín-Martín, Jorge
AU  - Mira-Escarti, José A
PY  - 2021
DO  - 10.3390/jcm10174019
SN  - 2077-0383
UR  - http://hdl.handle.net/10668/18507
T2  - Journal of clinical medicine
AB  - Immunomodulatory drugs have been used in patients with severe COVID-19. The objective of this study was to evaluate the effects of two different strategies, based either on an interleukin-1 inhibitor, anakinra, or on a JAK inhibitor, such as...
LA  - en
KW  - COVID-19
KW  - anakinra
KW  - baricitinib
KW  - corticosteroids
KW  - mortality
TI  - Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19.
TY  - research article
VL  - 10
ER  -